Treatment History

• FOLFOX/trastuzumab
• After 2 months, essentially stable disease, some decrease in thickening of GE junction, perhaps slight decrease in lung, LN. Symptomatic improvement in pain
• After 4 months, progressive disease with new liver lesions, lung lesions and some increase in prior lung lesions
• Paclitaxel/trastuzumab
• After two months of therapy, mixed response with response in lungs, but increase in size (but not number) of liver metastases
• Paclitaxel/ramucirumab
• After two months of therapy, increase in lymphadenopathy, and slightly in the lungs, but liver was stable
• Irinotecan/trastuzumab (MDACC recommended FOLFIRI): Ongoing